Header Logo

Connection

AMAN U BUZDAR to Lymphatic Metastasis

Back to Details
This is a "connection" page, showing publications AMAN U BUZDAR has written about Lymphatic Metastasis.
AMAN U BUZDAR
Connection Strength
0.597
Lymphatic Metastasis
  1. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1317-25.
    View in: PubMed
    Score: 0.057
  2. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9.
    View in: PubMed
    Score: 0.045
  3. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006 Mar 01; 106(5):1000-6.
    View in: PubMed
    Score: 0.034
  4. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005 Dec 20; 23(36):9304-11.
    View in: PubMed
    Score: 0.033
  5. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8.
    View in: PubMed
    Score: 0.026
  6. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001 Jun; 8(5):425-31.
    View in: PubMed
    Score: 0.024
  7. A retrospective study of first indicators of breast cancer recurrence. Oncology. 2000 Apr; 58(3):185-90.
    View in: PubMed
    Score: 0.022
  8. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-31-S17-34.
    View in: PubMed
    Score: 0.019
  9. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res. 1997 Sep; 3(9):1565-9.
    View in: PubMed
    Score: 0.019
  10. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.015
  11. Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med. 1994 Jan 01; 120(1):18-25.
    View in: PubMed
    Score: 0.014
  12. Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes. Am J Clin Oncol. 1992 Apr; 15(2):180-3.
    View in: PubMed
    Score: 0.013
  13. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992 Jan 15; 69(2):448-52.
    View in: PubMed
    Score: 0.013
  14. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012 May 15; 118(10):2603-14.
    View in: PubMed
    Score: 0.012
  15. Sixteen-week, dose-intense chemotherapy in adjuvant treatment of breast cancer. J Natl Cancer Inst. 1990 Jul 18; 82(14):1220-1.
    View in: PubMed
    Score: 0.011
  16. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989 Jan; 124(1):21-5.
    View in: PubMed
    Score: 0.010
  17. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988 Nov 15; 62(10):2098-104.
    View in: PubMed
    Score: 0.010
  18. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8.
    View in: PubMed
    Score: 0.010
  19. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 01; 25(28):4414-22.
    View in: PubMed
    Score: 0.009
  20. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54.
    View in: PubMed
    Score: 0.009
  21. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol. 2005 Oct 01; 23(28):7098-104.
    View in: PubMed
    Score: 0.008
  22. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer. 2005 Jul 15; 104(2):229-35.
    View in: PubMed
    Score: 0.008
  23. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7.
    View in: PubMed
    Score: 0.008
  24. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
    View in: PubMed
    Score: 0.008
  25. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45.
    View in: PubMed
    Score: 0.007
  26. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results Cancer Res. 1984; 96:141-7.
    View in: PubMed
    Score: 0.007
  27. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44.
    View in: PubMed
    Score: 0.007
  28. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1225-33.
    View in: PubMed
    Score: 0.007
  29. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002 Jun; 25(3):235-7.
    View in: PubMed
    Score: 0.006
  30. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001 Apr 15; 19(8):2240-6.
    View in: PubMed
    Score: 0.006
  31. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg. 2001 Apr; 181(4):313-8.
    View in: PubMed
    Score: 0.006
  32. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33.
    View in: PubMed
    Score: 0.006
  33. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3480-6.
    View in: PubMed
    Score: 0.006
  34. Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol. 2000 Sep; 7(8):581-7.
    View in: PubMed
    Score: 0.006
  35. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000 Aug; 18(15):2817-27.
    View in: PubMed
    Score: 0.006
  36. Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
    View in: PubMed
    Score: 0.006
  37. The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg. 2000 Jun; 179(6):446-52.
    View in: PubMed
    Score: 0.006
  38. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer. 2000 Mar 15; 88(6):1417-24.
    View in: PubMed
    Score: 0.006
  39. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33.
    View in: PubMed
    Score: 0.006
  40. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant. 2000 Feb; 14(1):32-41.
    View in: PubMed
    Score: 0.006
  41. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol. 1999 Dec; 6(8):762-7.
    View in: PubMed
    Score: 0.005
  42. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230(1):72-8.
    View in: PubMed
    Score: 0.005
  43. Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am. 1999 May-Jun; 5(3):159-64.
    View in: PubMed
    Score: 0.005
  44. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999 Feb; 17(2):460-9.
    View in: PubMed
    Score: 0.005
  45. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol. 1979; 12(1):27-40.
    View in: PubMed
    Score: 0.005
  46. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol. 1998 Dec; 5(8):673-80.
    View in: PubMed
    Score: 0.005
  47. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg. 1998 Dec; 176(6):502-9.
    View in: PubMed
    Score: 0.005
  48. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am. 1998 Jul-Aug; 4(4):230-6.
    View in: PubMed
    Score: 0.005
  49. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med. 1996 Jun; 37(6):931-8.
    View in: PubMed
    Score: 0.004
  50. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988 Dec 15; 62(12):2507-16.
    View in: PubMed
    Score: 0.003
  51. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol. 1987 Oct; 10(5):387-95.
    View in: PubMed
    Score: 0.002
  52. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol. 1987 Oct; 10(5):396-403.
    View in: PubMed
    Score: 0.002
  53. Management of locoregional recurrent breast cancer. Cancer. 1986 Oct 01; 58(7):1552-6.
    View in: PubMed
    Score: 0.002
  54. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41.
    View in: PubMed
    Score: 0.002
  55. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. Recent Results Cancer Res. 1984; 96:129-32.
    View in: PubMed
    Score: 0.002
  56. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec; 1(12):776-86.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.